OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis

Patrizia Nanni, Carla De Giovanni, Alessia Burocchi, Giordano Nicoletti, Lorena Landuzzi, Arianna Palladini, Marianna Lucia Ianzano, Ivano Arioli, Mario P. Colombo, Pier Luigi Lollini

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

This study evaluated the effects of combining an OX40 agonistic antibody (aOX40) with a cell vaccine targeting HER2/neu, called “Triplex”. Such HER2/neu cell vaccine included two biological adjuvants (interleukin 12 (IL12) and allogeneic histocompatibility antigens) and was previously found able to prevent autochthonous HER2/neu-driven mammary carcinogenesis. Timing of aOX40 administration, concomitantly or after cell vaccination, gave opposite results. Unexpectedly, vaccine efficacy was hampered by concomitant OX40 triggering. Such decreased immunoprevention was likely due to a reduced induction of anti-HER2/neu antibodies and to a higher level of Treg activation. On the contrary, aOX40 administration after the completion of vaccination slightly but significantly increased immunopreventive vaccine efficacy, and led to increased production of GM-CSF and IL10. In conclusion, OX40 triggering can either impair or ameliorate immunoprevention of HER2/neu-driven mammary carcinogenesis depending on the schedule of aOX40 administration.

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalOncoImmunology
Volume7
Issue number8
DOIs
Publication statusPublished - Jun 11 2018

Fingerprint

Interleukin-12
Carcinogenesis
Breast
Vaccines
Vaccination
Histocompatibility Antigens
Antibodies
Granulocyte-Macrophage Colony-Stimulating Factor
Interleukin-10
Appointments and Schedules

Keywords

  • Cancer vaccine
  • HER2/neu
  • immunoprevention
  • mammary cancer
  • OX40

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis. / Nanni, Patrizia; De Giovanni, Carla; Burocchi, Alessia; Nicoletti, Giordano; Landuzzi, Lorena; Palladini, Arianna; Ianzano, Marianna Lucia; Arioli, Ivano; Colombo, Mario P.; Lollini, Pier Luigi.

In: OncoImmunology, Vol. 7, No. 8, 11.06.2018, p. 1-7.

Research output: Contribution to journalArticle

Nanni, Patrizia ; De Giovanni, Carla ; Burocchi, Alessia ; Nicoletti, Giordano ; Landuzzi, Lorena ; Palladini, Arianna ; Ianzano, Marianna Lucia ; Arioli, Ivano ; Colombo, Mario P. ; Lollini, Pier Luigi. / OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis. In: OncoImmunology. 2018 ; Vol. 7, No. 8. pp. 1-7.
@article{190d9bb1efdc4083b18af7963302bf0f,
title = "OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis",
abstract = "This study evaluated the effects of combining an OX40 agonistic antibody (aOX40) with a cell vaccine targeting HER2/neu, called “Triplex”. Such HER2/neu cell vaccine included two biological adjuvants (interleukin 12 (IL12) and allogeneic histocompatibility antigens) and was previously found able to prevent autochthonous HER2/neu-driven mammary carcinogenesis. Timing of aOX40 administration, concomitantly or after cell vaccination, gave opposite results. Unexpectedly, vaccine efficacy was hampered by concomitant OX40 triggering. Such decreased immunoprevention was likely due to a reduced induction of anti-HER2/neu antibodies and to a higher level of Treg activation. On the contrary, aOX40 administration after the completion of vaccination slightly but significantly increased immunopreventive vaccine efficacy, and led to increased production of GM-CSF and IL10. In conclusion, OX40 triggering can either impair or ameliorate immunoprevention of HER2/neu-driven mammary carcinogenesis depending on the schedule of aOX40 administration.",
keywords = "Cancer vaccine, HER2/neu, immunoprevention, mammary cancer, OX40",
author = "Patrizia Nanni and {De Giovanni}, Carla and Alessia Burocchi and Giordano Nicoletti and Lorena Landuzzi and Arianna Palladini and Ianzano, {Marianna Lucia} and Ivano Arioli and Colombo, {Mario P.} and Lollini, {Pier Luigi}",
year = "2018",
month = "6",
day = "11",
doi = "10.1080/2162402X.2018.1465164",
language = "English",
volume = "7",
pages = "1--7",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Taylor and Francis Inc.",
number = "8",

}

TY - JOUR

T1 - OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis

AU - Nanni, Patrizia

AU - De Giovanni, Carla

AU - Burocchi, Alessia

AU - Nicoletti, Giordano

AU - Landuzzi, Lorena

AU - Palladini, Arianna

AU - Ianzano, Marianna Lucia

AU - Arioli, Ivano

AU - Colombo, Mario P.

AU - Lollini, Pier Luigi

PY - 2018/6/11

Y1 - 2018/6/11

N2 - This study evaluated the effects of combining an OX40 agonistic antibody (aOX40) with a cell vaccine targeting HER2/neu, called “Triplex”. Such HER2/neu cell vaccine included two biological adjuvants (interleukin 12 (IL12) and allogeneic histocompatibility antigens) and was previously found able to prevent autochthonous HER2/neu-driven mammary carcinogenesis. Timing of aOX40 administration, concomitantly or after cell vaccination, gave opposite results. Unexpectedly, vaccine efficacy was hampered by concomitant OX40 triggering. Such decreased immunoprevention was likely due to a reduced induction of anti-HER2/neu antibodies and to a higher level of Treg activation. On the contrary, aOX40 administration after the completion of vaccination slightly but significantly increased immunopreventive vaccine efficacy, and led to increased production of GM-CSF and IL10. In conclusion, OX40 triggering can either impair or ameliorate immunoprevention of HER2/neu-driven mammary carcinogenesis depending on the schedule of aOX40 administration.

AB - This study evaluated the effects of combining an OX40 agonistic antibody (aOX40) with a cell vaccine targeting HER2/neu, called “Triplex”. Such HER2/neu cell vaccine included two biological adjuvants (interleukin 12 (IL12) and allogeneic histocompatibility antigens) and was previously found able to prevent autochthonous HER2/neu-driven mammary carcinogenesis. Timing of aOX40 administration, concomitantly or after cell vaccination, gave opposite results. Unexpectedly, vaccine efficacy was hampered by concomitant OX40 triggering. Such decreased immunoprevention was likely due to a reduced induction of anti-HER2/neu antibodies and to a higher level of Treg activation. On the contrary, aOX40 administration after the completion of vaccination slightly but significantly increased immunopreventive vaccine efficacy, and led to increased production of GM-CSF and IL10. In conclusion, OX40 triggering can either impair or ameliorate immunoprevention of HER2/neu-driven mammary carcinogenesis depending on the schedule of aOX40 administration.

KW - Cancer vaccine

KW - HER2/neu

KW - immunoprevention

KW - mammary cancer

KW - OX40

UR - http://www.scopus.com/inward/record.url?scp=85048372013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048372013&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2018.1465164

DO - 10.1080/2162402X.2018.1465164

M3 - Article

AN - SCOPUS:85048372013

VL - 7

SP - 1

EP - 7

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

IS - 8

ER -